SHIPPEO
23.3.2022 11:05:05 CET | Business Wire | Press release
UNILIN , a Belgian manufacturer of flooring, panels and insulation products for the home, has chosen Shippeo , a global leader and European specialist in real-time transportation visibility, to boost service and savings.
Headquartered in Belgium, UNILIN owns 15 powerful brands (including the Quickstep flooring brand) and distributes its products in over 23 countries throughout Europe. The company operates eight key loading sites, consisting of plants, warehouses and a cross dock, and makes over 100,000 deliveries per year to specialised DIY and building supplies retailers via a network of 20 carrier partners.
A lack of visibility of external transport quality, lead times and proof of delivery led UNILIN to look for a solution that would help with supply chain optimisation and the streamlining of processes, thereby improving customer service and enabling the company to stay competitive in its market.
By implementing Shippeo’s real-time transportation visibility solution to collect location data for all deliveries, UNILIN was able to proactively inform customers about potential delays. Shippeo’s advanced ability to track Less-than-Truckload (LTL) was critical, as LTL is UNILIN’s main and most complex transportation method. Shippeo’s solution has been specifically engineered to overcome tracking challenges associated with LTL by using advanced integrations with carriers’ Transportation Management Systems (TMS) and highly accurate geofencing techniques. The live location data captured, along with automatically generated proofs of delivery, is accessible to users on the Shippeo platform portal. Delivery status information provided by Shippeo will also be made available to UNILIN customers via their own customer portal.
Following the success of the first business use case for real-time transportation visibility, UNILIN is now exploring taking advantage of Shippeo’s mobile application for more granular visibility of own fleet shipments thanks to its parcel scanning capabilities.
Shippeo’s Dennis van Bodegom, Director Northern Europe, is thrilled to be working with UNILIN: “Our organisations both share a strong commitment to excellence in service, and I’m sure Shippeo’s real-time visibility and predictive capabilities will lead to an optimised and proactive supply chain, for the benefit of UNILIN as well as their customers.”
Geert van Damme, Transport & Distribution Manager at UNILIN, said: “I did some market studies and a lot of companies came up with ideas. But the only one who could convince me to do a proof of concept was Shippeo. The ability to automatically provide our customers with real-time tracking for all our LTL deliveries is a game changer. The level of data and insight we now have access to also brings much more clarity around our delivery performance.”
About Shippeo (https://www.shippeo.com
)
LinkedIn, Facebook, Twitter
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries.
About Unilin (https://www.unilin.com
)
Unilin Group is a global reference for interior design and building. The company engineers, manufactures and markets laminate flooring, luxury vinyl tiles, sheet vinyl, engineered parquet, carpet tiles, broadloom carpet, raw and decorative panels, industrial floors, wall and roof systems and insulation boards. Unilin employs 7.500 people at 105 locations all over the globe, 30 of which are production sites. In 2020, Unilin achieved a turnover of €2.21 billion. Customers and partners know the company as Unilin, IVC or Godfrey Hirst, or through one of its brands, such as Quick-Step, Moduleo, Utherm, Pergo, Evola, Xtratherm or ClicWall. Unilin Group is proudly part of Mohawk Industries, the world's largest flooring company with a turnover of $ 10 billion and 41.600 employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005915/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom